AUSPERBIO
AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming hepatitis B treatment for a cure and advancing oligonucleotide therapeutics. Leveraging their innovative and proprietary Med-Oligoโข ASO platform with effective targeted delivery technologies, AusperBio strives to unleash the power of ASO therapeutics to treat a wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases.
AUSPERBIO
Social Links:
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2019-01-01
Address:
Hangzhou, Zhejiang, China
Country:
China
Website Url:
http://www.ausperbio.com
Total Employee:
101+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
50.67 M USD
Similar Organizations
Arctic Therapeutics
Arctic Therapeutics (AT) uses bioinformatic approaches and AI to eliminate major risks associated with traditional drug development.
EpiVario
EpiVario develops novel compounds to treat memory-related psychiatric disorders at the source of the disease.
Gritstone Bio
Gritstone Oncology is a clinical-stage biotech company that develops tumor-specific cancer immunotherapies to fight multiple cancer types.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
Halo Labs
Halo Labs is a biotechnology company that specializes in analytical instrumentation and biopharma.
VintaBio
VintaBio is a life sciences company that offers cell and gene therapy manufacturing services.
Investors List
BioVenture
BioVenture investment in Series A - AusperBio
Genesis Capital
Genesis Capital investment in Series A - AusperBio
InnoPinnacle Fund
InnoPinnacle Fund investment in Series A - AusperBio
Qiming Venture Partners
Qiming Venture Partners investment in Series A - AusperBio
Hankang Capital
Hankang Capital investment in Series A - AusperBio
Key Employee Changes
| Date | New article |
|---|---|
| 2024-01-03 | AusperBio Welcomes Dr. Will Wei as Head of CMC |
Official Site Inspections
http://www.ausperbio.com
- Host name: 8.208.94.211
- IP address: 8.208.94.211
- Location: United Kingdom
- Latitude: 51.4964
- Longitude: -0.1224
- Timezone: Europe/London
More informations about "AusperBio"
AusperBio - Crunchbase Company Profile & Funding
AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming hepatitis B treatment for a cure and advancing oligonucleotide therapeutics. Leveraging their โฆSee details»
Leadership - Ausperbio
AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming HBV treatment for cure and advancing oligonucleotide therapeutics. Leveraging our innovative and โฆSee details»
AusperBio - LinkedIn
AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and China, dedicated to advancing oligonucleotide and targeted delivery technologies for transformative โฆSee details»
AusperBio Company Profile - Office Locations, Competitors ... - Craft
AusperBio is a biopharmaceutical company that develops therapies for hepatitis B (HBV) treatment. It offers Med-Oligo ASO, a technology platform that enhances antisense โฆSee details»
Ausperbio
AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming HBV treatment for cure and advancing oligonucleotide therapeutics. Leveraging our innovative and โฆSee details»
AusperBio Company Profile 2024: Valuation, Funding & Investors
AusperBio General Information Description. Provider and developer of small interfering ribonucleic acid (siRNA) drugs designed for hepatitis B. The company focuses on innovative treatments โฆSee details»
AusperBio - Funding, Financials, Valuation & Investors - Crunchbase
AusperBio is a biotechnology company that develops innovative drugs for curing chronic hepatitis B and other major infectious diseases. Search Crunchbase. ... How much funding has this โฆSee details»
AusperBio Secures $37 Million in Series A Financing to Advance โฆ
Jul 15, 2024 AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and China, dedicated to advancing oligonucleotide and targeted delivery technologies for โฆSee details»
AusperBio Announces FDA Clearance of IND Application of AHB โฆ
Aug 25, 2023 (Together AusperBio), a clinical-stage biotech company committed to advancing antiviral therapies and vaccines, with a primary focus on achieving a functional cure for chronic โฆSee details»
AusperBio Highlights Major Advances in AHB-137 Clinical โฆ
Jul 5, 2024 AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a clinical-stage biotechnology company dedicated to advancing targeted โฆSee details»
AusperBio Raises $37 Million in Series A Round for Antisense ...
Jul 18, 2024 AusperBio, a Hangzhou-San Francisco biotech, completed a $37 million Series A financing. The company develops therapies based on its novel oligonucleotide and targeted โฆSee details»
AusperBio Receives Breakthrough Therapy Designation for AHB โฆ
Jul 11, 2024 AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and China, dedicated to advancing oligonucleotide and targeted delivery technologies for โฆSee details»
AusperBio Secures $37 Million in Series A Financing to ... - BioSpace
SAN FRANCISCO, July 14, 2024 /PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a privately held clinical-stage biotechnology โฆSee details»
AusperBio Announces First-in-Human Dosing of AHB-137, an โฆ
Mar 7, 2023 Ausper Biopharma Co., Ltd. and AusperBio Therapeutic, Inc. (Together Ausperbio) today announced the completion of the first cohort dosing in a Phase 1 clinical trial evaluating โฆSee details»
AusperBio Receives Breakthrough Therapy Designation for AHB โฆ
Jul 11, 2024 AusperBio (PRNewsfoto/AusperBio Therapeutics Inc.) The BTD was supported by clinical evidence from two parallel trials evaluating AHB-137's safety and efficacy in treating โฆSee details»
AusperBio Highlights Major Advances in AHB-137 Clinical โฆ
Jul 5, 2024 Dr. Chris Yang, Co-founder and CSO of AusperBio, added, "The rapid completion of Phase 2a enrollment positions us on an accelerated timeline to establish AHB-137's safety โฆSee details»
AusperBio Highlights Major Advances in AHB-137 ... - Pipelinereview
Jul 6, 2024 Dr. Chris Yang, Co-founder and CSO of AusperBio, added, โThe rapid completion of Phase 2a enrollment positions us on an accelerated timeline to establish AHB-137โs safety โฆSee details»
AusperBio Announces Major Progress in AHB-137 Clinical โฆ
Feb 14, 2024 (Together AusperBio), a clinical-stage biotechnology company dedicated to advancing oligonucleotide therapies, with a primary focus on achieving a functional cure for โฆSee details»
AusperBio Receives Breakthrough Therapy Designation for AHB
Jul 11, 2024 AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd., a clinical-stage biotechnology company dedicated to advancing targeted oligonucleotide therapies for โฆSee details»
AusperBio to Present Ongoing AHB-137 Clinical Data in Late
SAN FRANCISCO, Oct. 17, 2024 /PRNewswire/ -- AusperBio Therapeutic, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company, today โฆSee details»